Disrupting protein-protein interactions with aptamers
The selective disruption of protein-protein interactions holds potential for new drug discovery strategies.
Dr Katherine Bridge is a Research Fellow at the University of York investigating the role of the transcription factor Hypoxia-Inducible Factor (HIF) in blood cancer. She is working with binders from Aptamer Group to unravel the different transcription factor functions with the potential to improve cancer treatment with targeted therapeutics.
We spoke with her about what it is like to work at the cutting edge of research, the potential of aptamers over antibodies to target previously undruggable transcription factors, and the need for new understanding and solutions in the field of cancer.